{"count":221304,"next":"https://panelapp-aus.org/api/v1/activities/?format=json&page=1745","previous":"https://panelapp-aus.org/api/v1/activities/?format=json&page=1743","results":[{"created":"2020-07-05T17:29:14.386494+10:00","panel_name":"Periventricular Grey Matter Heterotopia","panel_id":19,"panel_version":"0.7","user_name":"Zornitza Stark","item_type":"entity","text":"Phenotypes for gene: MAP1B were changed from  to Intellectual disability; seizures; PVNH; dysmorphic features; Periventricular nodular heterotopia 9, MIM# 618918","entity_name":"MAP1B","entity_type":"gene"},{"created":"2020-07-05T17:28:44.325734+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"0.3224","user_name":"Zornitza Stark","item_type":"entity","text":"Phenotypes for gene: MAP1B were changed from Intellectual disability; seizures; PVNH; dysmorphic features to Intellectual disability; seizures; PVNH; dysmorphic features; Periventricular nodular heterotopia 9, MIM# 618918","entity_name":"MAP1B","entity_type":"gene"},{"created":"2020-07-05T17:28:23.789415+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"0.3223","user_name":"Zornitza Stark","item_type":"entity","text":"edited their review of gene: MAP1B: Changed phenotypes: Intellectual disability, seizures, PVNH, dysmorphic features, Periventricular nodular heterotopia 9, MIM# 618918","entity_name":"MAP1B","entity_type":"gene"},{"created":"2020-07-05T17:28:16.864086+10:00","panel_name":"Periventricular Grey Matter Heterotopia","panel_id":19,"panel_version":"0.6","user_name":"Zornitza Stark","item_type":"entity","text":"Publications for gene: MAP1B were set to ","entity_name":"MAP1B","entity_type":"gene"},{"created":"2020-07-05T17:27:08.584731+10:00","panel_name":"Periventricular Grey Matter Heterotopia","panel_id":19,"panel_version":"0.5","user_name":"Zornitza Stark","item_type":"entity","text":"Mode of inheritance for gene: MAP1B was changed from Unknown to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted","entity_name":"MAP1B","entity_type":"gene"},{"created":"2020-07-05T17:26:38.269405+10:00","panel_name":"Periventricular Grey Matter Heterotopia","panel_id":19,"panel_version":"0.4","user_name":"Zornitza Stark","item_type":"entity","text":"edited their review of gene: MAP1B: Changed phenotypes: Intellectual disability, seizures, PVNH, dysmorphic features, Periventricular nodular heterotopia 9, MIM# 618918","entity_name":"MAP1B","entity_type":"gene"},{"created":"2020-07-04T21:15:35.433265+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.57","user_name":"Zornitza Stark","item_type":"entity","text":"Marked gene: SUZ12 as ready","entity_name":"SUZ12","entity_type":"gene"},{"created":"2020-07-04T21:15:35.422861+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.57","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: suz12 has been classified as Green List (High Evidence).","entity_name":"SUZ12","entity_type":"gene"},{"created":"2020-07-04T21:15:32.194941+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.57","user_name":"Zornitza Stark","item_type":"entity","text":"Phenotypes for gene: SUZ12 were changed from  to Imagawa-Matsumoto syndrome, MIM# 618786","entity_name":"SUZ12","entity_type":"gene"},{"created":"2020-07-04T21:15:03.967790+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.56","user_name":"Zornitza Stark","item_type":"entity","text":"Publications for gene: SUZ12 were set to ","entity_name":"SUZ12","entity_type":"gene"},{"created":"2020-07-04T21:14:33.898855+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.55","user_name":"Zornitza Stark","item_type":"entity","text":"Mode of inheritance for gene: SUZ12 was changed from Unknown to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted","entity_name":"SUZ12","entity_type":"gene"},{"created":"2020-07-04T21:14:03.605756+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.54","user_name":"Zornitza Stark","item_type":"entity","text":"reviewed gene: SUZ12: Rating: GREEN; Mode of pathogenicity: None; Publications: 31736240, 28229514; Phenotypes: Imagawa-Matsumoto syndrome, MIM# 618786; Mode of inheritance: MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted","entity_name":"SUZ12","entity_type":"gene"},{"created":"2020-07-04T21:10:43.435798+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.54","user_name":"Zornitza Stark","item_type":"entity","text":"changed review comment from: At least 3 unrelated families reported.; to: At least 3 unrelated families reported, overgrowth is a key feature.","entity_name":"RNF125","entity_type":"gene"},{"created":"2020-07-04T21:09:18.933147+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.54","user_name":"Zornitza Stark","item_type":"entity","text":"Marked gene: RNF125 as ready","entity_name":"RNF125","entity_type":"gene"},{"created":"2020-07-04T21:09:18.919964+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.54","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: rnf125 has been classified as Green List (High Evidence).","entity_name":"RNF125","entity_type":"gene"},{"created":"2020-07-04T21:09:16.293324+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.54","user_name":"Zornitza Stark","item_type":"entity","text":"Phenotypes for gene: RNF125 were changed from  to Tenorio syndrome, MIM# 616260","entity_name":"RNF125","entity_type":"gene"},{"created":"2020-07-04T21:08:46.410236+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.53","user_name":"Zornitza Stark","item_type":"entity","text":"Publications for gene: RNF125 were set to ","entity_name":"RNF125","entity_type":"gene"},{"created":"2020-07-04T21:08:17.258526+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.52","user_name":"Zornitza Stark","item_type":"entity","text":"Mode of inheritance for gene: RNF125 was changed from Unknown to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted","entity_name":"RNF125","entity_type":"gene"},{"created":"2020-07-04T21:07:44.399714+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.51","user_name":"Zornitza Stark","item_type":"entity","text":"reviewed gene: RNF125: Rating: GREEN; Mode of pathogenicity: None; Publications: 25196541; Phenotypes: Tenorio syndrome, MIM# 616260; Mode of inheritance: MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted","entity_name":"RNF125","entity_type":"gene"},{"created":"2020-07-04T21:05:36.606607+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.51","user_name":"Zornitza Stark","item_type":"entity","text":"Marked gene: PTCH1 as ready","entity_name":"PTCH1","entity_type":"gene"},{"created":"2020-07-04T21:05:36.597068+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.51","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: ptch1 has been classified as Red List (Low Evidence).","entity_name":"PTCH1","entity_type":"gene"},{"created":"2020-07-04T21:05:34.305590+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.51","user_name":"Zornitza Stark","item_type":"entity","text":"Phenotypes for gene: PTCH1 were changed from  to Basal cell nevus syndrome, MIM# 109400","entity_name":"PTCH1","entity_type":"gene"},{"created":"2020-07-04T21:05:01.293377+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.50","user_name":"Zornitza Stark","item_type":"entity","text":"Classified gene: PTCH1 as Red List (low evidence)","entity_name":"PTCH1","entity_type":"gene"},{"created":"2020-07-04T21:05:01.267426+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.50","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: ptch1 has been classified as Red List (Low Evidence).","entity_name":"PTCH1","entity_type":"gene"},{"created":"2020-07-04T21:04:31.438248+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.49","user_name":"Zornitza Stark","item_type":"entity","text":"reviewed gene: PTCH1: Rating: RED; Mode of pathogenicity: None; Publications: ; Phenotypes: Basal cell nevus syndrome, MIM# 109400; Mode of inheritance: None","entity_name":"PTCH1","entity_type":"gene"},{"created":"2020-07-04T13:47:02.851979+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.49","user_name":"Zornitza Stark","item_type":"entity","text":"Marked gene: PPP2R5D as ready","entity_name":"PPP2R5D","entity_type":"gene"},{"created":"2020-07-04T13:47:02.842854+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.49","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: ppp2r5d has been classified as Red List (Low Evidence).","entity_name":"PPP2R5D","entity_type":"gene"},{"created":"2020-07-04T13:46:59.518866+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.49","user_name":"Zornitza Stark","item_type":"entity","text":"Phenotypes for gene: PPP2R5D were changed from  to Mental retardation, autosomal dominant 35, MIM# 616355","entity_name":"PPP2R5D","entity_type":"gene"},{"created":"2020-07-04T13:46:30.979931+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.48","user_name":"Zornitza Stark","item_type":"entity","text":"Publications for gene: PPP2R5D were set to ","entity_name":"PPP2R5D","entity_type":"gene"},{"created":"2020-07-04T13:46:07.952775+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.47","user_name":"Zornitza Stark","item_type":"entity","text":"Mode of inheritance for gene: PPP2R5D was changed from Unknown to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted","entity_name":"PPP2R5D","entity_type":"gene"},{"created":"2020-07-04T13:45:39.369651+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.46","user_name":"Zornitza Stark","item_type":"entity","text":"Classified gene: PPP2R5D as Red List (low evidence)","entity_name":"PPP2R5D","entity_type":"gene"},{"created":"2020-07-04T13:45:39.360529+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.46","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: ppp2r5d has been classified as Red List (Low Evidence).","entity_name":"PPP2R5D","entity_type":"gene"},{"created":"2020-07-04T13:45:09.240642+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.45","user_name":"Zornitza Stark","item_type":"entity","text":"reviewed gene: PPP2R5D: Rating: RED; Mode of pathogenicity: None; Publications: 26168268, 25972378, 25533962; Phenotypes: Mental retardation, autosomal dominant 35, MIM# 616355; Mode of inheritance: MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted","entity_name":"PPP2R5D","entity_type":"gene"},{"created":"2020-07-04T13:39:38.445109+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.45","user_name":"Zornitza Stark","item_type":"entity","text":"Marked gene: PIK3CA as ready","entity_name":"PIK3CA","entity_type":"gene"},{"created":"2020-07-04T13:39:38.434988+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.45","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: pik3ca has been classified as Green List (High Evidence).","entity_name":"PIK3CA","entity_type":"gene"},{"created":"2020-07-04T13:39:30.618899+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.45","user_name":"Zornitza Stark","item_type":"entity","text":"Phenotypes for gene: PIK3CA were changed from  to Cowden syndrome 5, MIM# 615108","entity_name":"PIK3CA","entity_type":"gene"},{"created":"2020-07-04T13:38:40.720009+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.44","user_name":"Zornitza Stark","item_type":"entity","text":"Publications for gene: PIK3CA were set to ","entity_name":"PIK3CA","entity_type":"gene"},{"created":"2020-07-04T13:38:16.328901+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.43","user_name":"Zornitza Stark","item_type":"entity","text":"Mode of inheritance for gene: PIK3CA was changed from Unknown to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted","entity_name":"PIK3CA","entity_type":"gene"},{"created":"2020-07-04T13:37:43.672083+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.42","user_name":"Zornitza Stark","item_type":"entity","text":"reviewed gene: PIK3CA: Rating: GREEN; Mode of pathogenicity: None; Publications: 23246288, 32362992, 31929958; Phenotypes: Cowden syndrome 5, MIM# 615108; Mode of inheritance: MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted","entity_name":"PIK3CA","entity_type":"gene"},{"created":"2020-07-04T13:33:15.688008+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.42","user_name":"Zornitza Stark","item_type":"entity","text":"Marked gene: PHF6 as ready","entity_name":"PHF6","entity_type":"gene"},{"created":"2020-07-04T13:33:15.673033+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.42","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: phf6 has been classified as Red List (Low Evidence).","entity_name":"PHF6","entity_type":"gene"},{"created":"2020-07-04T13:33:12.837429+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.42","user_name":"Zornitza Stark","item_type":"entity","text":"Phenotypes for gene: PHF6 were changed from  to Borjeson-Forssman-Lehmann syndrome, MIM# 301900","entity_name":"PHF6","entity_type":"gene"},{"created":"2020-07-04T13:32:40.040520+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.41","user_name":"Zornitza Stark","item_type":"entity","text":"Mode of inheritance for gene: PHF6 was changed from Unknown to X-LINKED: hemizygous mutation in males, biallelic mutations in females","entity_name":"PHF6","entity_type":"gene"},{"created":"2020-07-04T13:32:11.689448+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.40","user_name":"Zornitza Stark","item_type":"entity","text":"Classified gene: PHF6 as Red List (low evidence)","entity_name":"PHF6","entity_type":"gene"},{"created":"2020-07-04T13:32:11.678037+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.40","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: phf6 has been classified as Red List (Low Evidence).","entity_name":"PHF6","entity_type":"gene"},{"created":"2020-07-04T13:31:43.054839+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.39","user_name":"Zornitza Stark","item_type":"entity","text":"reviewed gene: PHF6: Rating: RED; Mode of pathogenicity: None; Publications: ; Phenotypes: Borjeson-Forssman-Lehmann syndrome, MIM# 301900; Mode of inheritance: X-LINKED: hemizygous mutation in males, biallelic mutations in females","entity_name":"PHF6","entity_type":"gene"},{"created":"2020-07-04T13:28:17.487740+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.39","user_name":"Zornitza Stark","item_type":"entity","text":"Marked gene: PDGFRB as ready","entity_name":"PDGFRB","entity_type":"gene"},{"created":"2020-07-04T13:28:17.478247+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.39","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: pdgfrb has been classified as Green List (High Evidence).","entity_name":"PDGFRB","entity_type":"gene"},{"created":"2020-07-04T13:28:00.174985+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.39","user_name":"Zornitza Stark","item_type":"entity","text":"Phenotypes for gene: PDGFRB were changed from  to Kosaki overgrowth syndrome, MIM# 616592","entity_name":"PDGFRB","entity_type":"gene"},{"created":"2020-07-04T13:27:25.426354+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.38","user_name":"Zornitza Stark","item_type":"entity","text":"Publications for gene: PDGFRB were set to ","entity_name":"PDGFRB","entity_type":"gene"},{"created":"2020-07-04T13:26:57.658931+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.37","user_name":"Zornitza Stark","item_type":"entity","text":"Mode of inheritance for gene: PDGFRB was changed from Unknown to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted","entity_name":"PDGFRB","entity_type":"gene"},{"created":"2020-07-04T13:26:26.783296+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.36","user_name":"Zornitza Stark","item_type":"entity","text":"reviewed gene: PDGFRB: Rating: GREEN; Mode of pathogenicity: None; Publications: 25454926, 32291752, 30941910, 29226947; Phenotypes: Kosaki overgrowth syndrome, MIM# 616592; Mode of inheritance: MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted","entity_name":"PDGFRB","entity_type":"gene"},{"created":"2020-07-04T13:24:04.484902+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.36","user_name":"Zornitza Stark","item_type":"panel","text":"removed gene:NPR3 from the panel","entity_name":null,"entity_type":null},{"created":"2020-07-04T13:23:18.283873+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.35","user_name":"Zornitza Stark","item_type":"entity","text":"changed review comment from: Four affected individuals from three unrelated families.; to: Four affected individuals from three unrelated families, however phenotype is more Marfanoid, rather than generalised overgrowth.","entity_name":"NPR3","entity_type":"gene"},{"created":"2020-07-04T13:23:00.333599+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.35","user_name":"Zornitza Stark","item_type":"entity","text":"edited their review of gene: NPR3: Changed rating: AMBER","entity_name":"NPR3","entity_type":"gene"},{"created":"2020-07-04T13:17:29.887225+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.35","user_name":"Zornitza Stark","item_type":"entity","text":"Marked gene: MED12 as ready","entity_name":"MED12","entity_type":"gene"},{"created":"2020-07-04T13:17:29.876992+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.35","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: med12 has been classified as Amber List (Moderate Evidence).","entity_name":"MED12","entity_type":"gene"},{"created":"2020-07-04T13:17:25.712094+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.35","user_name":"Zornitza Stark","item_type":"entity","text":"Phenotypes for gene: MED12 were changed from  to Lujan-Fryns syndrome, MIM# 309520; Opitz-Kaveggia syndrome, MIM# 305450","entity_name":"MED12","entity_type":"gene"},{"created":"2020-07-04T13:16:51.630426+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.34","user_name":"Zornitza Stark","item_type":"entity","text":"Mode of inheritance for gene: MED12 was changed from Unknown to X-LINKED: hemizygous mutation in males, biallelic mutations in females","entity_name":"MED12","entity_type":"gene"},{"created":"2020-07-04T13:16:23.570450+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.33","user_name":"Zornitza Stark","item_type":"entity","text":"Classified gene: MED12 as Amber List (moderate evidence)","entity_name":"MED12","entity_type":"gene"},{"created":"2020-07-04T13:16:23.558622+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.33","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: med12 has been classified as Amber List (Moderate Evidence).","entity_name":"MED12","entity_type":"gene"},{"created":"2020-07-04T13:15:53.458027+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.32","user_name":"Zornitza Stark","item_type":"entity","text":"reviewed gene: MED12: Rating: AMBER; Mode of pathogenicity: None; Publications: ; Phenotypes: Lujan-Fryns syndrome, MIM# 309520, Opitz-Kaveggia syndrome, MIM# 305450; Mode of inheritance: X-LINKED: hemizygous mutation in males, biallelic mutations in females","entity_name":"MED12","entity_type":"gene"},{"created":"2020-07-04T13:12:14.867980+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.32","user_name":"Zornitza Stark","item_type":"entity","text":"Classified gene: KMT5B as Amber List (moderate evidence)","entity_name":"KMT5B","entity_type":"gene"},{"created":"2020-07-04T13:12:14.858874+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.32","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: kmt5b has been classified as Amber List (Moderate Evidence).","entity_name":"KMT5B","entity_type":"gene"},{"created":"2020-07-04T13:11:45.666041+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.31","user_name":"Zornitza Stark","item_type":"entity","text":"changed review comment from: Tendency towards taller height reported in some affected individuals.; to: Tendency towards taller height reported in some affected individuals, overgrowth is not a prominent/consistent feature.","entity_name":"KMT5B","entity_type":"gene"},{"created":"2020-07-04T13:11:26.956237+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.31","user_name":"Zornitza Stark","item_type":"entity","text":"edited their review of gene: KMT5B: Changed rating: AMBER","entity_name":"KMT5B","entity_type":"gene"},{"created":"2020-07-04T13:09:00.523137+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.31","user_name":"Zornitza Stark","item_type":"entity","text":"Marked gene: GLI3 as ready","entity_name":"GLI3","entity_type":"gene"},{"created":"2020-07-04T13:09:00.497454+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.31","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: gli3 has been classified as Amber List (Moderate Evidence).","entity_name":"GLI3","entity_type":"gene"},{"created":"2020-07-04T13:08:56.097652+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.31","user_name":"Zornitza Stark","item_type":"entity","text":"Classified gene: GLI3 as Amber List (moderate evidence)","entity_name":"GLI3","entity_type":"gene"},{"created":"2020-07-04T13:08:56.084114+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.31","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: gli3 has been classified as Amber List (Moderate Evidence).","entity_name":"GLI3","entity_type":"gene"},{"created":"2020-07-04T13:08:25.427025+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.30","user_name":"Zornitza Stark","item_type":"entity","text":"reviewed gene: GLI3: Rating: AMBER; Mode of pathogenicity: None; Publications: ; Phenotypes: ; Mode of inheritance: None","entity_name":"GLI3","entity_type":"gene"},{"created":"2020-07-04T13:05:46.892401+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.30","user_name":"Zornitza Stark","item_type":"entity","text":"Tag SV/CNV tag was added to gene: DIS3L2.","entity_name":"DIS3L2","entity_type":"gene"},{"created":"2020-07-04T13:04:30.774861+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.30","user_name":"Zornitza Stark","item_type":"entity","text":"Marked gene: DIS3L2 as ready","entity_name":"DIS3L2","entity_type":"gene"},{"created":"2020-07-04T13:04:30.764878+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.30","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: dis3l2 has been classified as Green List (High Evidence).","entity_name":"DIS3L2","entity_type":"gene"},{"created":"2020-07-04T13:04:27.833908+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.30","user_name":"Zornitza Stark","item_type":"entity","text":"Phenotypes for gene: DIS3L2 were changed from  to Perlman syndrome, MIM# 267000","entity_name":"DIS3L2","entity_type":"gene"},{"created":"2020-07-04T13:03:58.491604+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.29","user_name":"Zornitza Stark","item_type":"entity","text":"Publications for gene: DIS3L2 were set to ","entity_name":"DIS3L2","entity_type":"gene"},{"created":"2020-07-04T13:03:29.227036+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.28","user_name":"Zornitza Stark","item_type":"entity","text":"Mode of inheritance for gene: DIS3L2 was changed from Unknown to BIALLELIC, autosomal or pseudoautosomal","entity_name":"DIS3L2","entity_type":"gene"},{"created":"2020-07-04T13:03:00.019797+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.27","user_name":"Zornitza Stark","item_type":"entity","text":"reviewed gene: DIS3L2: Rating: GREEN; Mode of pathogenicity: None; Publications: 22306653, 28328139, 29950491; Phenotypes: Perlman syndrome, MIM# 267000; Mode of inheritance: BIALLELIC, autosomal or pseudoautosomal","entity_name":"DIS3L2","entity_type":"gene"},{"created":"2020-07-04T12:51:49.788313+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.27","user_name":"Zornitza Stark","item_type":"entity","text":"Marked gene: AKT2 as ready","entity_name":"AKT2","entity_type":"gene"},{"created":"2020-07-04T12:51:49.778787+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.27","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: akt2 has been classified as Green List (High Evidence).","entity_name":"AKT2","entity_type":"gene"},{"created":"2020-07-04T12:51:44.196181+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.27","user_name":"Zornitza Stark","item_type":"entity","text":"Classified gene: AKT2 as Green List (high evidence)","entity_name":"AKT2","entity_type":"gene"},{"created":"2020-07-04T12:51:44.186091+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.27","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: akt2 has been classified as Green List (High Evidence).","entity_name":"AKT2","entity_type":"gene"},{"created":"2020-07-04T12:50:29.729918+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.26","user_name":"Zornitza Stark","item_type":"entity","text":"gene: AKT2 was added\ngene: AKT2 was added to Overgrowth. Sources: Expert list\nMode of inheritance for gene: AKT2 was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted\nPublications for gene: AKT2 were set to 21979934\nPhenotypes for gene: AKT2 were set to Hypoinsulinemic hypoglycemia with hemihypertrophy, MIM#\t240900\nMode of pathogenicity for gene: AKT2 was set to Other\nReview for gene: AKT2 was set to GREEN\nAdded comment: Three unrelated individuals reported with same de novo recurring missense variant, postulated to be activating, E17K. \nSources: Expert list","entity_name":"AKT2","entity_type":"gene"},{"created":"2020-07-04T12:44:03.213935+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.25","user_name":"Zornitza Stark","item_type":"entity","text":"Marked gene: ABCC9 as ready","entity_name":"ABCC9","entity_type":"gene"},{"created":"2020-07-04T12:44:03.204179+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.25","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: abcc9 has been classified as Green List (High Evidence).","entity_name":"ABCC9","entity_type":"gene"},{"created":"2020-07-04T12:44:00.873717+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.25","user_name":"Zornitza Stark","item_type":"entity","text":"Phenotypes for gene: ABCC9 were changed from  to Hypertrichotic osteochondrodysplasia, MIM# 239850; Cantu syndrome","entity_name":"ABCC9","entity_type":"gene"},{"created":"2020-07-04T12:43:32.573853+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.24","user_name":"Zornitza Stark","item_type":"entity","text":"Publications for gene: ABCC9 were set to ","entity_name":"ABCC9","entity_type":"gene"},{"created":"2020-07-04T12:43:02.333753+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.23","user_name":"Zornitza Stark","item_type":"entity","text":"Mode of inheritance for gene: ABCC9 was changed from Unknown to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted","entity_name":"ABCC9","entity_type":"gene"},{"created":"2020-07-04T12:42:30.401893+10:00","panel_name":"Overgrowth","panel_id":151,"panel_version":"0.22","user_name":"Zornitza Stark","item_type":"entity","text":"reviewed gene: ABCC9: Rating: GREEN; Mode of pathogenicity: None; Publications: 22610116, 22608503; Phenotypes: Hypertrichotic osteochondrodysplasia, MIM# 239850, Cantu syndrome; Mode of inheritance: MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted","entity_name":"ABCC9","entity_type":"gene"},{"created":"2020-07-04T08:29:32.872969+10:00","panel_name":"Rasopathy","panel_id":164,"panel_version":"0.31","user_name":"Zornitza Stark","item_type":"entity","text":"Phenotypes for gene: PTPN11 were changed from LEOPARD syndrome 1, 151100 AD (for reporting use Noonan syndrome with multiple lentigines); Metachondromatosis, 156250 AD; Noonan syndrome 1, 163950 AD; Leukemia, juvenile myelomonocytic, somatic, 607785 to LEOPARD syndrome 1, 151100 AD (for reporting use Noonan syndrome with multiple lentigines); Noonan syndrome 1, 163950 AD","entity_name":"PTPN11","entity_type":"gene"},{"created":"2020-07-03T20:41:16.459716+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"0.3223","user_name":"Zornitza Stark","item_type":"entity","text":"Marked gene: MRAS as ready","entity_name":"MRAS","entity_type":"gene"},{"created":"2020-07-03T20:41:16.450565+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"0.3223","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: mras has been classified as Green List (High Evidence).","entity_name":"MRAS","entity_type":"gene"},{"created":"2020-07-03T20:40:30.380363+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"0.3223","user_name":"Zornitza Stark","item_type":"entity","text":"Classified gene: MRAS as Green List (high evidence)","entity_name":"MRAS","entity_type":"gene"},{"created":"2020-07-03T20:40:30.367903+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"0.3223","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: mras has been classified as Green List (High Evidence).","entity_name":"MRAS","entity_type":"gene"},{"created":"2020-07-03T20:40:06.937264+10:00","panel_name":"Rasopathy","panel_id":164,"panel_version":"0.30","user_name":"Zornitza Stark","item_type":"entity","text":"Classified gene: MRAS as Green List (high evidence)","entity_name":"MRAS","entity_type":"gene"},{"created":"2020-07-03T20:40:06.924883+10:00","panel_name":"Rasopathy","panel_id":164,"panel_version":"0.30","user_name":"Zornitza Stark","item_type":"entity","text":"Gene: mras has been classified as Green List (High Evidence).","entity_name":"MRAS","entity_type":"gene"},{"created":"2020-07-03T20:38:17.219394+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"0.3222","user_name":"Zornitza Stark","item_type":"entity","text":"changed review comment from: Two unrelated individuals reported with de novo variants in this gene. Rated as LIMITED by ClinGen. \nSources: Expert list; to: Two unrelated individuals reported with de novo variants in this gene initially. Rated as LIMITED by ClinGen in 2018. Note 4 further individuals reported since.\r\nSources: Expert list","entity_name":"MRAS","entity_type":"gene"},{"created":"2020-07-03T20:37:51.894090+10:00","panel_name":"Mendeliome","panel_id":137,"panel_version":"0.3222","user_name":"Zornitza Stark","item_type":"entity","text":"edited their review of gene: MRAS: Changed rating: GREEN; Changed publications: 28289718, 31173466, 31108500, 31173466","entity_name":"MRAS","entity_type":"gene"},{"created":"2020-07-03T20:37:23.016130+10:00","panel_name":"Rasopathy","panel_id":164,"panel_version":"0.29","user_name":"Zornitza Stark","item_type":"entity","text":"changed review comment from: Two unrelated individuals reported with de novo variants in this gene. Rated as LIMITED by ClinGen. \nSources: Expert list; to: Two unrelated individuals reported with de novo variants in this gene. Rated as LIMITED by ClinGen in 2018. Note 4 further individuals reported since.\r\nSources: Expert list","entity_name":"MRAS","entity_type":"gene"},{"created":"2020-07-03T20:37:01.640011+10:00","panel_name":"Rasopathy","panel_id":164,"panel_version":"0.29","user_name":"Zornitza Stark","item_type":"entity","text":"edited their review of gene: MRAS: Changed publications: 28289718, 31173466, 31108500, 31173466","entity_name":"MRAS","entity_type":"gene"}]}